San Diego-dependent Viking Therapeutics marked itself as a significant competitor inside the weight loss drug sector in February right after revealing promising information from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in Mar